GlaxoSmithKline logo

Corporate Responsibility Report 2008

Environmental fundamentals

We have been working to reduce the fundamental environmental impacts of our operations for many years.

This involves using treatment and disposal systems to control emissions and wastes from over 80 manufacturing facilities, more than 20 research laboratories, numerous offices and warehouses and a large fleet of vehicles.

Our fundamental emissions include:

  • Wastewater
  • General solid and hazardous waste
  • Ozone depleting substances released from our equipment and production processes and when patients use our inhaler products
  • Volatile organic compounds, primarily solvents

We aim to create a culture where fundamental environmental considerations are part of everyday business decisions. While we continue to manage fundamental emissions, we are now moving towards sustainability, changing our production and business processes to avoid waste at source rather than simply treating the waste and emissions that arise.